Radiopharma Leadership Progenics is now a Lantheus company and benefits from Lantheus' leadership in radiopharmaceuticals. SNMMI recognition for LNTH-2513 demonstrates strong clinical data and market validation that can support upsell to imaging centers and hospitals seeking leading PET tracers. Cross-sell opportunities with Neuraceq and other radiopharmaceuticals.

Manufacturing Capacity The CMIT-Shreveport collaboration to produce Neuraceq demonstrates scalable manufacturing and regional supply capabilities, creating selling points for regional hospitals and clinics requiring reliable radiopharmacy supply and potential contract manufacturing for new products.

Market Engagement Active participation in top industry conferences signals a robust pipeline of clinical data and market messaging opportunities; leverage these events to schedule product demonstrations, key opinion leader engagements, and data-driven sales outreach to oncology and nuclear medicine departments.

Financial Readiness Revenue and funding levels indicate available budget for expansion, partnerships, and trial-related supply expansions; combined with recent strong quarterly results, suggests capacity to invest in sales programs, training, and procurement for customer operations.

Leadership Change A recent departure of a senior VP Commercial suggests changes in go-to-market leadership; this creates an opening to align with new decision-makers, tailor value propositions around portfolio expansion, and accelerate channel partnerships with updated priorities.